TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD

INTRODUCTION: Several risk factors for severe COVID-19 specific for patients with inflammatory rheumatic and musculoskeletal diseases (RMDs) have been identified so far. Evidence regarding the influence of different RMD treatments on outcomes of SARS-CoV-2 infection is still poor. METHODS: Data from...

Descripción completa

Detalles Bibliográficos
Autores principales: Regierer, Anne Constanze, Hasseli, Rebecca, Schäfer, Martin, Hoyer, Bimba F, Krause, Andreas, Lorenz, Hanns-Martin, Pfeil, Alexander, Richter, Jutta, Schmeiser, Tim, Schulze-Koops, Hendrik, Strangfeld, Anja, Voll, Reinhard E, Specker, Christof, Mueller-Ladner, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Infections
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529615/
https://www.ncbi.nlm.nih.gov/pubmed/34670840
http://dx.doi.org/10.1136/rmdopen-2021-001896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529615/
https://www.ncbi.nlm.nih.gov/pubmed/34670840
http://dx.doi.org/10.1136/rmdopen-2021-001896

Ejemplares similares